Seattle Children's launches BrainChild Bio to accelerate CAR T-cell therapies for children with brain tumors
Seattle Children's today announced the launch of BrainChild Bio, Inc. to accelerate the advancement of chimeric antigen receptor (CAR) T-cell therapies in Central Nervous System (CNS) tumors.
- Seattle Children's today announced the launch of BrainChild Bio, Inc. to accelerate the advancement of chimeric antigen receptor (CAR) T-cell therapies in Central Nervous System (CNS) tumors.
- BrainChild Bio will be granted an exclusive license to novel CAR T-cell technology for CNS tumors developed at Seattle Children’s and will build upon the pioneering CAR T-cell therapy and clinical translational work of Michael Jensen, M.D., and his team at Seattle Children’s Therapeutics.
- Seattle Children’s has provided the initial equity funding for BrainChild Bio which will operate as an independently managed corporation.
- The launch of BrainChild Bio is a natural progression of Seattle Children’s Therapeutics’ goal to expand access to potentially life-changing therapies through collaborations with biotech companies.